Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma

被引:0
作者
Junbin Liao
Huilin Jin
Shaoqiang Li
Lixia Xu
Zhenwei Peng
Guangyan Wei
Jianting Long
Yu Guo
Ming Kuang
Qi Zhou
Sui Peng
机构
[1] Sun Yat-sen University,Department of Liver Surgery, The First Affiliated Hospital
[2] Sun Yat-Sen University,Guangdong Research Institute of Gastroenterology, The Sixth Affiliated Hospital
[3] Sun Yat-sen University,Department of Oncology, The First Affiliated Hospital
[4] Sun Yat-sen University,Precision Medicine Institute, The First Affiliated Hospital
[5] Sun Yat-sen University,Department of Radiation Oncology, The First Affiliated Hospital
[6] Sun Yat-sen University,Clinical Trials Unit, The First Affiliated Hospital
[7] Sun Yat-sen University,Department of General Surgery, The First Affiliated Hospital
[8] Sun Yat-sen University,Division of Interventional Ultrasound, The First Affiliated Hospital
[9] Sun Yat-sen University,Department of General Surgery, Huiya Hospital of The First Affiliated Hospital
[10] Sun Yat-sen University,Department of Gastroenterology and Hepatology, The First Affiliated Hospital
来源
Journal of Experimental & Clinical Cancer Research | / 38卷
关键词
Hepatocellular carcinoma; Apatinib; Irradiation; Radiosensitization; PI3K/AKT pathway;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 241 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2016)Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma Gastroenterology 150 835-853
[3]  
Soerjomataram I(2016)Hepatocellular carcinoma Nat Rev Dis Primers 2 16018-459
[4]  
Siegel RL(2016)Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma J Clin Oncol 34 452-1639
[5]  
Torre LA(2013)Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma J Clin Oncol 31 1631-425
[6]  
Jemal A(2015)The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence Nat Rev Cancer 15 409-2201
[7]  
Bruix J(2017)Recent developments in radiotherapy N Engl J Med 377 2200-390
[8]  
Reig M(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-34
[9]  
Sherman M(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-1353
[10]  
Llovet JM(2018)The safety and efficacy of combination therapy of sorafenib and radiotherapy for advanced hepatocellular carcinoma: a retrospective study Intern Med 57 1345-1047